Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
about
SLC transporters as therapeutic targets: emerging opportunitiesRenal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of actionSelective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.An Influence of the Estimated Glomerular Filtration Rate on Improvement in Metabolic Parameters by Sodium-Glucose Cotransporter 2 Inhibitors.Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.SLC Transporters: Structure, Function, and Drug Discovery.Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models.The modification of natural products for medical use.Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Industrial natural product chemistry for drug discovery and development.Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.Clinical implication of SGLT2 inhibitors in type 2 diabetes.Natural product and natural product derived drugs in clinical trials.Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.Safety and Effectiveness of Tofogliflozin in Elderly Japanese Patients with Type 2 Diabetes Mellitus: a Post-Marketing Study (J-STEP/EL Study).Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance.Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.Designed Spiroketal Protein Modulation.Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans.Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans.A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus.In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP.The utilization of spirocyclic scaffolds in novel drug discovery.Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug classDesigned Spiroketal Protein Modulation
P2860
Q27014726-EEFCD923-DB31-4BAF-83C2-BF6221FEA25CQ27027105-95AA88D0-0EB4-473A-9D4C-E15E08F4459FQ34318349-AE4E6BFC-6750-4D9D-A1EA-4ED44B75F1B8Q34726437-3E3DA136-C0B9-4D06-94C6-0029584B7B5DQ35049845-C8E836A1-F14B-4036-AE4E-790F1FE94B52Q36857002-5752E185-C49B-4E3F-BBA4-7768677F376EQ37219076-DED6ED8C-E750-4117-93EB-BBAC12942185Q37279747-4FC7B711-D51E-4950-910C-F69298B0E232Q37536310-B0CE0295-3F84-426F-80C0-36F8386E39C6Q37689655-D2EFB7D9-B3C1-4504-9D91-5B7AF18D6538Q38085691-B7E266C3-D7D1-4019-B0D5-0F410200D8D8Q38130748-B86F4EEC-800A-48EC-81EE-F363200BFC02Q38154186-5F148BE6-51B5-4D3D-B7E2-60EFEB0EF14BQ38196340-7A6C871B-EB3C-4DB1-96D1-3D25527D6AEDQ38221980-1A576CBB-4671-4E43-B5D0-BF4ADE2A60D1Q38247457-A1011F34-7EB1-4F87-83BB-4C774582426EQ38669170-372F1C6F-9FE3-4638-A43E-84B8AA70718AQ38936746-A4A01A9F-155C-4518-BA6E-121DAA6EB242Q40363925-E37A50FD-403D-4E1D-99F5-49BF6C983245Q40934119-F25E8773-A53A-4210-B60C-81390BCFB516Q41922447-BBACEDC5-FFB7-469B-8245-B3388F6B8327Q42259127-4A6F6B40-8C92-4C03-9A41-A06BB0F310EAQ44204062-B5544603-9829-47C5-AFFA-883C8E07059CQ45424734-04B319D1-D3DB-42C4-9A6D-B258E048AAECQ47374718-500EA12F-49BB-4112-8F3F-6B872871332BQ51744102-6A7244DC-D676-4E78-A4CB-0C1F3234A9C0Q53008268-AD62472A-85D4-473B-BE1E-486BB6F01C11Q53755762-215717F9-5BAC-42AA-9C8E-6B446F421E10Q57485826-A5E239E4-E4D5-458D-90CC-6C2775242E30Q57531344-EDCAB7AC-89CF-4880-A535-6ACA30882DA8
P2860
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Discovery of tofogliflozin, a ...... treatment of type 2 diabetes.
@ast
Discovery of tofogliflozin, a ...... treatment of type 2 diabetes.
@en
Discovery of tofogliflozin, a ...... treatment of type 2 diabetes.
@nl
type
label
Discovery of tofogliflozin, a ...... treatment of type 2 diabetes.
@ast
Discovery of tofogliflozin, a ...... treatment of type 2 diabetes.
@en
Discovery of tofogliflozin, a ...... treatment of type 2 diabetes.
@nl
prefLabel
Discovery of tofogliflozin, a ...... treatment of type 2 diabetes.
@ast
Discovery of tofogliflozin, a ...... treatment of type 2 diabetes.
@en
Discovery of tofogliflozin, a ...... treatment of type 2 diabetes.
@nl
P2093
P356
P1476
Discovery of tofogliflozin, a ...... treatment of type 2 diabetes.
@en
P2093
Hiroharu Matsuoka
Hitoshi Hagita
Kazuharu Ozawa
Kazumi Morikawa
Keisuke Yamamoto
Koji Takano
Koji Yamaguchi
Koo-Hyeon Ahn
Kyoko Takami
Marina Yamaguchi
P304
P356
10.1021/JM300884K
P407
P577
2012-08-28T00:00:00Z